Centrum Medyczne Oporow — Clinical Trial Site

79 Registered trials

30 Currently recruiting

Organisation

Centrum Medyczne Oporow

Location

Wroclaw, Poland

Identifier

ORG-100043338

Address

Ul. Ul. Ludwika Solskiego 4a/1, 52-416, Poland

Departments

#40043: Rheumatology
#PL10012: Gastrology
1913
3025:Cardiology
3552: NA
3552: Rumatologia
40043: Centrum Medyczne Oporow
Centrum Medyczne Oporów
Dermatology
Dermatology Department
Gastroenterology
Medical Centre Oporow
n/a
na
not applicable/nie dotyczy
PL10002: Gastroneterology
PL10023: Gastroenterologia
PL10034: Gastroenterologia
Rheumatology

Clinical trials at this site (79)

Search interface

A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’… Ended

2022-502966-26-01 Sjögren’s syndrome 5 2023-10-27
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended

2024-515027-11-00 Crohn’s disease 4 2023-06-29
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Ended

2022-500700-22-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-25
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Ended

2022-501480-41-00 Psoriatic Arthritis 5 2023-04-06
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 4 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn's Disease Ended

2023-504740-33-00 Fistulizing perianal Crohn's Disease 5 2022-11-22
Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended

2024-511068-10-00 Sjögren’s Syndrome 5 2022-08-04
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended

2023-507974-42-00 Moderate to Severe Ulcerative Colitis 4 2021-12-01
ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2024-515156-21-00 Ulcerative Colitis 5 2020-01-09
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi… Ended

2023-506664-14-00 Rheumatoid Arthritis 5 2024-10-24
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Ended

2022-502481-24-00 Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) 4 2024-05-23
A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended

2023-505857-42-00 Chronic Kidney Disease, Type 2 diabetes 4 2024-04-19
A Study to Investigate Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moder… Ended

2022-502183-20-00 Moderately to Severely Active Ulcerative Colitis 5 2024-02-26
Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504673-20-00 Ulcerative Colitis 4 2023-12-06
This is a clinical trial (study), to be conducted in several clinical sites worldwide, of an oral study drug which will be investigated in a… Ended

2023-503957-36-00 Moderate-to-Severe pruritus in adult subjects with nota 10 2023-12-04
A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab Ended

2022-502393-16-00 Moderately to Severely Active Ulcerative Colitis 5 2023-09-06
Ecopipam Tablets to Study Tourette’s Disorder in Children, Adolescents and Adults (D1AMOND) Ended

2023-503494-38-00 Tourette’s Disorder 5 2023-07-20
ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended

2022-500535-36-01 Moderately to severely active ulcerative colitis 5 2023-06-12
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended

2024-511089-36-00 Crohn’s disease 4 2023-03-17
C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan… Ended

2024-513270-21-00 migraine headaches with or without aura 6 2023-03-14
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15